kneat.com (TSE:KSI) PT Set at C$6.00 by CIBC

kneat.com (TSE:KSI) has been assigned a C$6.00 price objective by analysts at CIBC in a report issued on Tuesday, BayStreet.CA reports. The firm presently has an “outperform” rating on the stock. CIBC’s price objective suggests a potential upside of 25.00% from the stock’s current price.

Separately, Ventum Cap Mkts upgraded kneat.com to a “strong-buy” rating in a report on Wednesday, August 7th.

kneat.com Trading Up 0.6 %

KSI opened at C$4.80 on Tuesday. kneat.com has a 52 week low of C$2.68 and a 52 week high of C$5.17. The business has a fifty day simple moving average of C$4.76 and a 200-day simple moving average of C$4.44. The firm has a market cap of C$412.80 million, a P/E ratio of -30.00, a P/E/G ratio of 597.67 and a beta of 1.08. The company has a quick ratio of 1.50, a current ratio of 1.47 and a debt-to-equity ratio of 95.14.

kneat.com (TSE:KSI) last released its earnings results on Tuesday, August 6th. The company reported C($0.04) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of C($0.04). The firm had revenue of C$11.68 million during the quarter, compared to analyst estimates of C$11.45 million. kneat.com had a negative return on equity of 51.13% and a negative net margin of 31.19%. On average, equities analysts expect that kneat.com will post -0.12 earnings per share for the current year.

About kneat.com

kneat.com, inc., together with its subsidiaries, designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific. The company offers the Kneat Gx platform, a configurable off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.